The Soluble Fms-like Tyrosine Kinase-1 Contributes to Structural and Functional Changes in Endothelial Cells in Chronic Kidney Disease.
Fms-like tyrosine kinase-1 (sFlt-1)
chronic kidney disease (CKD)
endothelial dysfunction
endothelial stiffness
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Dec 2022
16 Dec 2022
Historique:
received:
24
10
2022
revised:
09
12
2022
accepted:
13
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Endothelial cells are a critical target of the soluble Fms-like tyrosine kinase-1 (sFlt-1), a soluble factor increased in different diseases with varying degrees of renal impairment and endothelial dysfunction, including chronic kidney disease (CKD). Although the mechanisms underlying endothelial dysfunction are multifactorial and complex, herein, we investigated the damaging effects of sFlt-1 on structural and functional changes in endothelial cells. Our results evidenced that sera from patients with CKD stiffen the endothelial cell cortex in vitro, an effect correlated with sFlt-1 levels and prevented by sFlt-1 neutralization. Besides, we could show that recombinant sFlt-1 leads to endothelial stiffening in vitro and in vivo. This was accompanied by cytoskeleton reorganization and changes in the endothelial barrier function, as observed by increased actin polymerization and endothelial cell permeability, respectively. These results depended on the activation of the p38 MAPK and were blocked by the specific inhibitor SB203580. However, sFlt-1 only minimally affected the expression of stiffness-sensitive genes. These findings bring new insight into the mechanism of action of sFlt-1 and its biological effects that cannot be exclusively ascribed to the regulation of angiogenesis.
Identifiants
pubmed: 36555698
pii: ijms232416059
doi: 10.3390/ijms232416059
pmc: PMC9787493
pii:
doi:
Substances chimiques
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
FLT1 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SE2824/3-1
Organisme : Deutsche Forschungsgemeinschaft
ID : KFO342 - ZA428/18-1
Références
Front Med (Lausanne). 2020 Oct 07;7:542567
pubmed: 33117828
Nat Cell Biol. 2006 Nov;8(11):1223-34
pubmed: 17060906
J Clin Invest. 2016 Jul 1;126(7):2561-74
pubmed: 27270170
FASEB J. 2019 Dec;33(12):13762-13774
pubmed: 31585052
PLoS One. 2015 Jul 01;10(7):e0132047
pubmed: 26132137
Vasc Cell. 2011 Jul 13;3(1):15
pubmed: 21752276
Trends Mol Med. 2021 Apr;27(4):314-331
pubmed: 33309601
Physiol Rev. 2006 Jan;86(1):279-367
pubmed: 16371600
Kidney Int. 2019 May;95(5):1091-1102
pubmed: 30824181
Pediatr Res. 2005 May;57(5 Pt 2):1R-7R
pubmed: 15817508
Kidney Int. 2005 May;67(5):1680-2
pubmed: 15840012
N Engl J Med. 2004 Feb 12;350(7):672-83
pubmed: 14764923
Oncotarget. 2017 May 29;8(33):55684-55714
pubmed: 28903453
Microvasc Res. 2001 Nov;62(3):252-62
pubmed: 11678628
Biochem Biophys Res Commun. 1996 Sep 13;226(2):324-8
pubmed: 8806634
Nephrol Dial Transplant. 2013 Sep;28(9):2356-63
pubmed: 23828162
Cell Tissue Res. 2014 Mar;355(3):727-37
pubmed: 24643677
Hypertension. 2011 Feb;57(2):146-7
pubmed: 21149825
Cardiovasc Res. 2011 Feb 15;89(3):671-9
pubmed: 21139021
Curr Vasc Pharmacol. 2010 Jan;8(1):122-8
pubmed: 19485913
Sci Rep. 2019 Dec 3;9(1):18209
pubmed: 31796790
Pflugers Arch. 2011 Aug;462(2):209-17
pubmed: 21318292
J Am Soc Nephrol. 2009 Oct;20(10):2235-45
pubmed: 19608702
Int J Nanomedicine. 2011;6:179-95
pubmed: 21499414
J Immunol. 2001 Jun 1;166(11):6877-84
pubmed: 11359848
Eur Biophys J. 2012 Nov;41(11):939-47
pubmed: 22940754
Am J Cardiol. 2009 Dec 1;104(11):1478-83
pubmed: 19932778
Nephrol Dial Transplant. 2020 Sep 1;35(9):1478-1487
pubmed: 31071222
Respir Res. 2017 Jun 2;18(1):116
pubmed: 28578669
PLoS One. 2013 Nov 20;8(11):e80905
pubmed: 24278345
J Clin Invest. 2013 Feb;123(2):540-1
pubmed: 23485580
Biol Reprod. 2015 Sep;93(3):73
pubmed: 26203176
Hypertension. 2008 Aug;52(2):402-7
pubmed: 18574068
PLoS One. 2014 Jul 09;9(7):e101779
pubmed: 25007257
Basic Res Cardiol. 2015 May;110(3):30
pubmed: 25893874
Pulm Circ. 2014 Dec;4(4):535-51
pubmed: 25610592
J Hypertens. 2007 Mar;25(3):639-47
pubmed: 17278981
Kidney Res Clin Pract. 2015 Jun;34(2):76-82
pubmed: 26484026
Circulation. 1997 Nov 4;96(9):3042-7
pubmed: 9386173
FASEB J. 2012 Jan;26(1):355-62
pubmed: 21911594
Antioxidants (Basel). 2022 Sep 30;11(10):
pubmed: 36290681
J Am Soc Nephrol. 2012 Apr;23(4):652-60
pubmed: 22282588
Kidney Int. 2020 Mar;97(3):502-515
pubmed: 32008804
J Am Coll Cardiol. 2011 Jul 19;58(4):386-94
pubmed: 21757116
Kidney Int. 2014 Feb;85(2):393-403
pubmed: 24048373
Front Physiol. 2018 Mar 06;9:83
pubmed: 29563877
PLoS One. 2014 Mar 14;9(3):e91897
pubmed: 24632840
Trends Biochem Sci. 2000 Jun;25(6):257-60
pubmed: 10838561
Am J Pathol. 2020 Apr;190(4):732-741
pubmed: 32035884
J Am Soc Nephrol. 2021 Aug;32(8):1853-1863
pubmed: 34155060
Hypertension. 2011 Feb;57(2):231-7
pubmed: 21149827
Am J Respir Crit Care Med. 2001 Nov 1;164(9):1601-5
pubmed: 11719296
Antioxid Redox Signal. 2019 Mar 1;30(7):945-959
pubmed: 29433330
Cell Motil Cytoskeleton. 2005 Oct;62(2):124-32
pubmed: 16145686
Kidney Int. 2013 Feb;83(2):213-22
pubmed: 22913982
J Am Soc Nephrol. 2012 Jan;23(1):155-64
pubmed: 22034638